Showing results (301-310 of 555) with videos related to
Sort By:
Pageof 56
Dermatology and Therapy|November 30, 2021
Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16Jonathan I Silverberg, Mark Boguniewicz, Jill Waibel, et al.Dermatology and Therapy|August 6, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b TrialMelinda J Gooderham, Giampiero Girolomoni, Julian O Moore, et al.Journal of Drugs in Dermatology : JDD|February 2, 2024
Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic DermatitisLawrence F Eichenfield, Jonathan I Silverberg, Adelaide A Hebert, et al.Journal of Drugs in Dermatology : JDD|January 28, 2020
Topical Agents for the Treatment of Atopic DermatitisLawrence F. Eichenfield, Thomas Luger, Kim Papp, et al.Dermatitis : Contact, Atopic, Occupational, Drug|March 14, 2023
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient SurveyJonathan I Silverberg, Jennifer A Mohawk, Joshua Cirulli, et al.Dermatologic Therapy|October 21, 2022
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomesEric Simpson, April Armstrong, Mark Boguniewicz, et al.The British Journal of Dermatology|June 20, 2022
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: Classification: EpidemiologyMaria C Schneeweiss, Julien Kirchgesner, Richard Wyss, et al.Annals of Clinical and Laboratory Science|April 28, 2010
Green tea (Camelia sinensis) suppresses B cell production of IgE without inducing apoptosisEhab Hassanain, Jonathan I Silverberg, Kevin B Norowitz, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 17, 2020
Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized studyJonathan I Silverberg, Emma Guttman-Yassky, Melinda Gooderham, et al.American Journal of Clinical Dermatology|October 20, 2022
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III StudiesLisa Bloudek, Lawrence F Eichenfield, Jonathan I Silverberg, et al.Pageof 56